Oppenheimer analyst Hartaj Singh maintained a Buy rating on Moderna (NASDAQ:MRNA) on Wednesday, setting a price target of $206, which is approximately 37.60% above the present share price of $149.71.
Singh expects Moderna to post earnings per share (EPS) of -$0.69 for the second quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Moderna, with an average price target of $167.82.
The analysts price targets range from a high of $208 to a low of $80.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $570.75 million and a net profit of -$275.04 million. The company's market cap is $59.96 billion.
According to TipRanks.com, Oppenheimer analyst Hartaj Singh is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 14.4% and a 45.16% success rate.
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.